HKSE:02509 (China)
Â
Ordinary Shares - Class H
HK$
17.58
-0.37 (-2.06%)
Aug 18
Business Description
Qyuns Therapeutics Co Ltd
ISIN : CNE1000069W9
Share Class Description:
HKSE:02509: Ordinary Shares - Class HTotal Employee Number:
337Compare
Compare
Traded in other countries / regions
02509.Hong Kong IPO Date
2024-03-20Description
Qyuns Therapeutics Co Ltd is a clinical-stage biotech company focused on biologic therapies for autoimmune and allergic diseases, with a self-developed drug pipeline. It has built a pipeline that covers the four disease areas in the field, including skin, rheumatic, respiratory, and digestive diseases. The group is principally engaged in the research and development, manufacturing, and commercialisation of biologic therapies for autoimmune and allergic diseases. Key revenue is generated from the PRC.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.8 | |||||
Equity-to-Asset | 0.43 | |||||
Debt-to-Equity | 0.84 | |||||
Debt-to-EBITDA | 1.78 | |||||
Interest Coverage | 17.45 | |||||
Piotroski F-Score | 8/9 | |||||
Altman Z-Score | 3.14 | |||||
Beneish M-Score | 0.82 | |||||
WACC vs ROIC | ||||||
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 54.66 | |||||
9-Day RSI | 60.94 | |||||
14-Day RSI | 61.06 | |||||
3-1 Month Momentum % | -2.2 | |||||
6-1 Month Momentum % | -19.65 | |||||
12-1 Month Momentum % | -41.21 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.22 | |||||
Quick Ratio | 2.2 | |||||
Cash Ratio | 2.07 | |||||
Days Inventory | 23.86 | |||||
Days Sales Outstanding | 16.93 | |||||
Days Payable | 434.11 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.5 | |||||
Shareholder Yield % | -4.75 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 88.54 | |||||
Operating Margin % | 41.43 | |||||
Net Margin % | 39.11 | |||||
EBITDA Margin % | 40.61 | |||||
FCF Margin % | 48.86 | |||||
OCF Margin % | 49.8 | |||||
ROE % | 82.88 | |||||
ROA % | 25.72 | |||||
ROIC % | 51.65 | |||||
3-Year ROIIC % | 278.02 | |||||
ROC (Joel Greenblatt) % | 107.46 | |||||
ROCE % | 42.52 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 11.28 | |||||
Forward PE Ratio | 17.16 | |||||
PE Ratio without NRI | 11.28 | |||||
Price-to-Owner-Earnings | 11.33 | |||||
PS Ratio | 4.43 | |||||
PB Ratio | 5.17 | |||||
Price-to-Tangible-Book | 5.34 | |||||
Price-to-Free-Cash-Flow | 9.15 | |||||
Price-to-Operating-Cash-Flow | 8.98 | |||||
EV-to-EBIT | 9.34 | |||||
EV-to-EBITDA | 9.34 | |||||
EV-to-Revenue | 3.79 | |||||
EV-to-FCF | 7.76 | |||||
Price-to-Graham-Number | 1.64 | |||||
| Price-to-Net-Current-Asset-Value | 17.07 | |||||
| Price-to-Net-Cash | 26.64 | |||||
Earnings Yield (Greenblatt) % | 10.71 | |||||
FCF Yield % | 11.06 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Qyuns Therapeutics Co Ltd Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil HK$) | 889.061 | ||
| EPS (TTM) (HK$) | 1.559 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 75.13 | ||
| 14-Day RSI | 61.06 | ||
| 14-Day ATR (HK$) | 0.810806 | ||
| 20-Day SMA (HK$) | 16.7755 | ||
| 12-1 Month Momentum % | -41.21 | ||
| 52-Week Range (HK$) | 13.21 - 36.5 | ||
| Shares Outstanding (Mil) | 223.37 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 8 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Qyuns Therapeutics Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Qyuns Therapeutics Co Ltd Stock Events
| Event | Date | Price (HK$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Qyuns Therapeutics Co Ltd Frequently Asked Questions
What is Qyuns Therapeutics Co Ltd(HKSE:02509)'s stock price today?
The current price of HKSE:02509 is HK$17.58. The 52 week high of HKSE:02509 is HK$36.50 and 52 week low is HK$13.21.
When is next earnings date of Qyuns Therapeutics Co Ltd(HKSE:02509)?
The next earnings date of Qyuns Therapeutics Co Ltd(HKSE:02509) is .
Does Qyuns Therapeutics Co Ltd(HKSE:02509) pay dividends? If so, how much?
Qyuns Therapeutics Co Ltd(HKSE:02509) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Qyuns Therapeutics Co Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers